High-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival and progression-free survival in patients with limited-stage small cell lung cancer who had not progressed following concurrent chemoradiotherapy compared to placebo after cCRT. The safety profile for Imfinzi was consistent with its known profile, and no new safety signals were identified. These data will be presented at a forthcoming medical meeting and shared with global regulatory authorities. The second experimental arm testing the efficacy of Imjudo added to Imfinzi as a secondary endpoint remains blinded and will continue to the next planned analysis. Imfinzi is approved in the US, EU, Japan, China and many other countries around the world for the treatment of extensive-stage SCLC based on the CASPIAN Phase III trial. Imfinzi is also the only approved immunotherapy and the global standard of care in the curative-intent setting of unresectable, Stage III non-small cell lung cancer in patients whose disease has not progressed after CRT based on the PACIFIC Phase III trial.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
